Study #2021-0663
NRG-BR007: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score
MD Anderson Study Status
Enrolling
Treatment Agent
Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Description
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Stage I Breast Cancer
Study phase:
Phase III
Physician name:
Simona Shaitelman
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.